en عمومى General پژوهشي orginal article <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Background & Aims</span></i></b><b><span style="font-size:9.0pt">:</span></b> <span style="font-size:9.0pt">Cytomegalovirus (CMV) is a member of herpesvirus family with high prevalence in the normal population, which can lead to life-threatening latent infection. This virus has potential oncogenicity and can be reactivated in terms of immune suppression. This study was conducted to investigate the prevalence of CMV in the patients with chronic lymphocytic leukemia (CLL).</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Materials & Methods</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">To determine CMV prevalence, serum samples were collected from CLL patients after establishment of diagnosis by oncologist in<b>&nbsp;</b>Imam Khomeini Hospital, Urmia, Iran as well as from age-matched healthy subjects as control group. A total of 65 study participants, 33 males and 32 females, were included in this study in two groups, study group (n=31) and control group (n=34). All serum samples were tested for CMV-specific IgG and IgM antibodies using the enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed by SPSS version 16.0. Student&#39;s t-test and Chi-square test were used for comparison of variables and between the categorical variables, respectively. The statistical significance considered as <i>P < 0.05</i>.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Results</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> &nbsp;The prevalence of CMV infection in all participants was 84.6%. The prevalence of CMV current infection (IgM positive) and previous infection (IgG positive only) were respectively 29.03% and 70.97% in the patient group and 97.05% and 2.95% in the control group.<b> </b>&nbsp;&nbsp;</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Conclusion</span></i></b><b><span style="font-size:9.0pt">: </span></b>&nbsp;<a name="_Hlk118791388"><span style="font-size:9.0pt">Based on our results, previous exposure to CMV was significantly higher in the CLL patients compared with the control group. </span></a><span style="font-size:9.0pt">Good treatment and care strategies for the CLL patients can play an important role in preventing the reactivation of latent viral infections. Further studies and longtime monitoring should be done to know the factors affecting the reactivation of latent CMV infection and other latent viral infections in the CLL patients.</span></span></span></span> Chronic Lymphocytic Leukemia, Cytomegalovirus, Iran, Seroprevalence 223 228 http://ijrabms.umsu.ac.ir/browse.php?a_code=A-10-234-1&slc_lang=en&sid=1 Zakieh Rostamzadeh khameneh drrostamzadeh@yahoo.com 10031947532846002266 10031947532846002266 Yes Associate Professor of Laboratory Sciences, Department of Laboratory Sciences, Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran Nasim Valizadeh 10031947532846002267 10031947532846002267 No Adult hematology and oncology specialist (adult hematology and oncology), Tehran, Iran Mohaddeseh Nemati 10031947532846002268 10031947532846002268 No PhD student in clinical biochemistry, Urmia University of Medical Sciences, Urmia, Iran Ali Eishi 10031947532846002269 10031947532846002269 No Professor of Hematology & Oncology, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran